GLMD

GalmedF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

Curated Events

Active

Recent Headlines

New

Curated events

No material screener or newswire events are stored for this ticker yet.

Sentiment decomposition

30-day score

Company-55%

Macro-30%

Pulse-15%

The 30-day sentiment score is a decayed blend of Company, Macro, and Pulse components.

Recent headlines

Headline

Time

Relevance

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

2026-05-14

55%

External coverage

Galmed Issues CEO Letter to Shareholders

2025-12-01

23%

External coverage

Galmed Pharmaceuticals: Q3 Earnings Snapshot

2025-11-26

23%

External coverage

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-11-26

23%

External coverage

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

2025-11-18

23%

External coverage

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

2025-11-17

23%

External coverage

Galmed Pharmaceuticals: Q2 Earnings Snapshot

2025-08-28

23%

External coverage

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

2025-08-28

23%

External coverage

As of 2026-05-14 • Updated scheduledSource: News desk